$496.87
0.59% yesterday
Nasdaq, Jul 29, 10:04 pm CET
ISIN
US46120E6023
Symbol
ISRG

Intuitive Surgical Target price 2025 - Analyst rating & recommendation

Intuitive Surgical Classifications & Recommendation:

Buy
67%
Hold
31%
Sell
3%

Intuitive Surgical Price Target

Target Price $601.80
Price $496.87
Potential 21.12%
Number of Estimates 31
31 Analysts have issued a price target Intuitive Surgical 2026 . The average Intuitive Surgical target price is $601.80. This is 21.12% higher than the current stock price. The highest price target is $708.75 42.64% , the lowest is $444.40 10.56% .
A rating was issued by 39 analysts: 26 Analysts recommend Intuitive Surgical to buy, 12 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Intuitive Surgical stock has an average upside potential 2026 of 21.12% . Most analysts recommend the Intuitive Surgical stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032


Dec '24 2025
Estimates
Revenue Billion $ 8.35 9.97
17.24% 19.37%
EBITDA Margin 28.25% 39.73%
12.82% 40.66%
Net Margin 27.81% 28.75%
10.18% 3.39%

37 Analysts have issued a sales forecast Intuitive Surgical 2025 . The average Intuitive Surgical sales estimate is $10.0b . This is 9.02% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $10.4b 13.67% , the lowest is $9.4b 3.18% .

This results in the following potential growth metrics:

Revenue Estimates

2024 $8.4b 17.24%
2025 $10.0b 19.37%
2026 $11.4b 14.31%
2027 $13.1b 14.66%
2028 $14.3b 9.59%
2029 $16.1b 12.73%
2030 $18.2b 12.85%
2031 $19.0b 4.54%
2032 $20.9b 9.60%

37 Intuitive Surgical Analysts have issued a net profit forecast 2025. The average Intuitive Surgical net profit estimate is $2.9b . This is 9.93% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $3.1b 18.78% , the lowest is $2.7b 2.24% .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $2.3b 29.18%
2025 $2.9b 23.42%
2026 $3.3b 15.34%
2027 $3.9b 17.39%
2028 $4.3b 11.38%
2029 $5.2b 19.35%
2030 $6.1b 18.72%
2031 $6.5b 5.76%
2032 $7.0b 8.41%

Net Margin

2024 27.81% 10.18%
2025 28.75% 3.39%
2026 29.01% 0.90%
2027 29.70% 2.38%
2028 30.19% 1.65%
2029 31.96% 5.86%
2030 33.62% 5.19%
2031 34.02% 1.19%
2032 33.64% 1.12%

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032


Dec '24 2025
Estimates
Earnings Per Share $ 6.42 8.00
27.63% 24.61%
P/E 62.13
EV/Sales 16.91

37 Analysts have issued a Intuitive Surgical forecast for earnings per share. The average Intuitive Surgical EPS is $8.00 . This is 11.58% higher than earnings per share in the financial year 2024. The highest EPS forecast is $8.64 20.50% , the lowest is $7.44 3.77% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $6.42 27.63%
2025 $8.00 24.61%
2026 $9.22 15.25%
2027 $10.83 17.46%
2028 $12.06 11.36%
2029 $14.40 19.40%
2030 $17.09 18.68%
2031 $18.07 5.73%
2032 $19.59 8.41%

P/E ratio

Current 69.30 9.08%
2025 62.13 10.34%
2026 53.86 13.31%
2027 45.88 14.82%
2028 41.19 10.22%
2029 34.52 16.19%
2030 29.07 15.79%
2031 27.49 5.44%
2032 25.36 7.75%

Based on analysts' sales estimates for 2025, the Intuitive Surgical stock is valued at an EV/Sales of 16.91 and an P/S ratio of 17.87 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 18.43 7.99%
2025 16.91 8.25%
2026 14.79 12.52%
2027 12.90 12.79%
2028 11.77 8.75%
2029 10.44 11.29%
2030 9.25 11.38%
2031 8.85 4.34%
2032 8.08 8.76%

P/S ratio

Current 19.48 5.78%
2025 17.87 8.27%
2026 15.63 12.52%
2027 13.63 12.79%
2028 12.44 8.75%
2029 11.03 11.29%
2030 9.78 11.38%
2031 9.35 4.34%
2032 8.53 8.76%

Current Intuitive Surgical Upgrades & Downgrades

Analyst Rating Action Date
Piper Sandler
Overweight
Overweight
Unchanged Jul 23 2025
Truist Securities
Buy
Buy
Unchanged Jul 23 2025
UBS
Neutral
Neutral
Unchanged Jul 23 2025
BTIG
Buy
Buy
Unchanged Jul 23 2025
RBC Capital
Outperform
Outperform
Unchanged Jul 23 2025
Wells Fargo
Overweight
Overweight
Unchanged Jul 23 2025
Evercore ISI Group
In-Line
In-Line
Unchanged Jul 08 2025
Analyst Rating Date
Unchanged
Piper Sandler:
Overweight
Overweight
Jul 23 2025
Unchanged
Truist Securities:
Buy
Buy
Jul 23 2025
Unchanged
UBS:
Neutral
Neutral
Jul 23 2025
Unchanged
BTIG:
Buy
Buy
Jul 23 2025
Unchanged
RBC Capital:
Outperform
Outperform
Jul 23 2025
Unchanged
Wells Fargo:
Overweight
Overweight
Jul 23 2025
Unchanged
Evercore ISI Group:
In-Line
In-Line
Jul 08 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today